Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.63
+0.24 (1.38%)
At close: Aug 14, 2026, 4:00 PM EDT
17.58
-0.05 (-0.28%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Takeda Pharmaceutical Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
-163,436-152,390107,928144,067317,017230,059
Depreciation & Amortization
659,989678,583720,982728,002664,400583,151
Other Amortization
42,54442,54440,414---
Loss (Gain) From Sale of Assets
-3,883-15,197-5,703-1,780-6,797-7,174
Asset Writedown & Restructuring Costs
173,356145,716106,529150,01764,39454,515
Loss (Gain) From Sale of Investments
2501,006-60220,7573,991-11,195
Loss (Gain) on Equity Investments
1,1032,1773,986-6,4738,63015,367
Stock-Based Compensation
74,43472,77572,86770,87160,67243,374
Other Operating Activities
117,24066,31270,153-133,114-109,887116,403
Change in Accounts Receivable
-189,219-70,166-58,95915,10475,127127,294
Change in Inventory
-81,629-61,293-34,973-115,743-79,155-46,148
Change in Accounts Payable
1,720-3,150-7,118-9,895-84,804125,157
Change in Other Net Operating Assets
321,162334,51441,678-145,46963,568-107,698
Operating Cash Flow
953,6311,041,4311,057,182716,344977,1561,123,105
Operating Cash Flow Growth
-13.49%-1.49%47.58%-26.69%-13.00%11.10%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-181,901-176,003-200,795-175,420-140,657-123,252
Sale of Property, Plant & Equipment
1,1656,454788,6069621,815
Cash Acquisitions
------49,672
Divestitures
14,49633,32520,55619,9597,95828,196
Sale (Purchase) of Intangibles
-257,200-234,930-147,046-305,310-493,032-62,785
Investment in Securities
-10,267-8,607-11,4071,25512,1038,580
Other Investing Activities
10,05610,620-28,446-12,9525,564-1,007
Investing Cash Flow
-423,651-369,141-367,060-463,862-607,102-198,125

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
--27,490277,00040,000-
Long-Term Debt Issued
-586,0601,024,460100,00075,000249,334
Total Debt Issued
402,505586,0601,051,950377,000115,000249,334
Short-Term Debt Repaid
--341,780----2
Long-Term Debt Repaid
--243,204-1,366,264-375,487-400,071-849,809
Total Debt Repaid
-412,738-584,984-1,366,264-375,487-400,071-849,811
Net Debt Issued (Repaid)
-10,2331,076-314,3141,513-285,071-600,477
Repurchase of Common Stock
-1,007-51,603-51,860-2,326-26,929-77,531
Common Dividends Paid
-316,737-311,901-302,498-287,188-279,416-283,665
Other Financing Activities
-134,291-134,392-82,753-66,415-117,732-108,592
Financing Cash Flow
-462,268-496,820-751,425-354,416-709,148-1,070,265

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
43,26234,472-11,38526,20422,92928,758
Miscellaneous Cash Flow Adjustments
--11---
Net Cash Flow
110,974209,941-72,687-75,730-316,165-116,527

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
771,730865,428856,387540,924836,499999,853
Free Cash Flow Growth
-15.29%1.06%58.32%-35.34%-16.34%11.13%
Free Cash Flow Margin
16.71%19.21%18.69%12.69%20.77%28.02%
Free Cash Flow Per Share
488.79549.46533.47342.28532.85633.95
Levered Free Cash Flow
541,444672,783735,617121,361480,297929,111
Unlevered Free Cash Flow
658,038765,360817,171193,481553,4051,005,631

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
120,264121,380112,984100,375108,555108,207
Cash Income Tax Paid
153,029172,562150,413202,039185,966140,423
Change in Working Capital
52,034199,905-59,372-256,003-25,26498,605
SEC Filings: 10-K · 10-Q